The MA3RS Study Investigators. Circulation 2017;136:787-97. Conclusions: Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging is a novel approach to the identification of aortic wall cellular inflammation in patients with abdominal aortic aneurysms, and predicts the rate of aneurysm growth and clinical outcome. However, it does not provide an independent prediction of aneurysm expansion or clinical outcomes in a model incorporating known clinical risk factors.
Efficacy and Safety of Aspirin in Patients With Peripheral Vascular Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mahmoud AN, Elgendy AY, Rambarat C, Mahtta D, Elgendy IY, Bavry AA. PLoS ONE 2017; 12:e0175283. Conclusions: Aspirin use in patients with peripheral vascular disease (PVD) might not be associated with improved cardiovascular outcomes or worse bleeding outcomes. Larger randomized trials assessing the efficacy and safety of aspirin in the contemporary era are mandatory to confirm the current findings. Guideline recommendations regarding the use of aspirin among patients with PVD need to be updated.
Summary: An electronic search of databases was conducted from inception until January 2017 for all randomized trials comparing aspirin with either placebo or control (no aspirin) in patients with PVD. The primary efficacy outcome was all-cause mortality, and the primary safety outcome was major bleeding. Other outcomes of interest were major adverse cardiac and cerebrovascular events, myocardial infarction, stroke, and intracranial hemorrhage. Random-effects summary risk ratios (RRs) were calculated using the Der-Simonian and Liard model. The quality of evidence was assessed by GRADE tool and Cochrane risk of bias assessment tool. A total of 6560 patients (3290 in the aspirin group vs 3270 in the control arm) from 11 trials were included. The mean age was 62 year, 60% were female, 67% designated smokers, and 32% were diabetic. Only two trials were considered to have a low risk of bias, one representing about 50% of the patients included in this metaanalysis.
1 Compared with control, aspirin was associated with a similar incidence of all-cause mortality (8.5% vs 7.7%; RR, 0.93; 95% confidence interval [CI], 0.8-1.1) and this remained so when limited explicitly to patients without a prior history of ischemic events as well as other pertinent subgroup analysis. When evaluating for major adverse cardiac and cerebrovascular events (RR, 1.0; 95% CI, 0.83-1.20), myocardial infarction (RR, 0.91; 95% CI, 0.67-1.23), and stroke (RR, 0.72; 95% CI, 0.43-1.22) there was no statistical difference found. Comparing aspirin versus control for the primary safety outcome of major bleeding (1.3% vs 1.1%; RR, 1.59; 95% CI, 0.96-2.62), there was no statistical difference with a similar finding for intracranial hemorrhage (RR, 1.38; 95% CI, 0.59-3.21).
Comments: Reevaluating "standard care" is always appropriate because new findings might suggest a need to modify such recommendations. This study has limitations, most notably in not being able to control for other ongoing treatments like statins and antihypertensive agents, all of which could mask the effects of aspirin alone. In addition, the majority of patients are from one randomized, controlled trial.
1 This author believes that this study does support the concept that, in asymptomatic patients with PVD, aspirin provides little cardiovascular event protection. Whether aspirin decreases cardiovascular risk in symptomatic patients with PVS remains controversial, but this study suggests a lack of effective in such patients as well. 
Conclusions:
The findings of this study suggests a potential role for metformin in limiting abdominal aortic aneurysm (AAA) growth.
Summary: The aim of this study was to examine the association of diabetes treatments, particularly metformin, with AAA growth inhibition. AAA growth studied using ultrasound surveillance constituted the patients included in cohort 1, repeated computed tomography for those in cohort 2, and more a detailed repeat computed tomography (including AAA volume) for those in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. In cohort 1, there were 1357 patients with a mean initial AAA diameter of 36.9 mm who were followed for a mean of 4.9 scans and for 3.6 years. The mean annual AAA growth rate was significantly slower (P ¼ .012) in the 118 diabetic patients prescribed metformin (1.03 mm) but not in the 99 diabetic patients not prescribed metformin (1.60 mm) when compared with the 1140 nondiabetics patients not receiving metformin (1.62 mm). A cohort of 2287 patients with a mean initial aortic diameter of 40.9 mm was followed with a mean of 2.9 scans and for 2.9 years. Mean annual AAA growth was significantly slower (P ¼ .004) in the 39 diabetic patients prescribed metformin (1.40 mm), but not in the 30 diabetic patients not prescribed metformin (2.18 mm), than in the 218 nondiabetic patients not receiving metformin (2.55 mm). In cohort 3, the mean annual AAA growth was significantly slower (P ¼ .018) in the 16 diabetic patients prescribed metformin (0.37 mm), but not in the 3 diabetic patients not prescribed metformin (0.95 mm), than in the 34 nondiabetic patients not receiving metformin (1.46 mm). Adjusting for other risk factors did not change these findings in any cohort. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1, adjusted odds ratio [OR] 
